Person · CIK 1744425

Pamela Esposito

Director at Kymera Therapeutics

Earlier: Replimune Group

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$10.4M

Noticed on Form 144$6.3M

Bought on Form 4$0

Companies2

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

Company	Security	Held	Shares or units	As of
Kymera Therapeutics KYMR	Common Stock	Directly	1,000	May 19, 2026 · Filing · EDGAR
Kymera Therapeutics KYMR	Stock Option (Right to Buy) exercise $99.87, expires Jun 23, 2036, into Common Stock	Directly	6,068	Jun 24, 2026 · Filing · EDGAR
Replimune Group	Common Stock	Directly	263,436	Sep 12, 2023 · Filing · EDGAR
Replimune Group	Employee Stock Option (right to buy) exercise $3.30, expires Jul 26, 2027, into Common Stock	Directly	86,033	Sep 12, 2023 · Filing · EDGAR

Sold and noticed by quarter

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table

Quarter	Sold (Form 4)	Noticed (Form 144)
Q1 2026	$790K	$798K
Q4 2025	$2.3M	$2.3M
Q2 2025	$245K	$216K
Q4 2024	$123K	$117K
Q3 2024	$652K	$654K
Q2 2024	—	$473K
Q3 2023	$945K	$1.7M
Q2 2023	$108K	—
Q4 2022	$375K	Not machine-readable
Q2 2022	$51K	Not machine-readable
Q3 2021	$1.8M	Not machine-readable
Q1 2021	$2.4M	Not machine-readable
Q4 2020	$526K	Not machine-readable
Q3 2020	$135K	Not machine-readable

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice date	Noticed	Planned sale	Outcome	Links
Kymera Therapeutics KYMR · Morgan Stanley Smith Barney · 10b5-1 plan adopted Sep 17, 2025 · 4 notices
Mar 20, 2026	2,500 · ~$199K	Mar 20, 2026	Sold as noticed Sold 2,500 in 3 sales, Mar 20 to Mar 20 · $198K Form 4	Filing · EDGAR
Feb 20, 2026	2,500 · ~$216K	Feb 20, 2026	Sold as noticed Sold 2,500 in 2 sales, Feb 20 to Feb 20 · $218K Form 4	Filing · EDGAR
Jan 20, 2026	5,500 · ~$382K	Jan 20, 2026	Partly sold Sold 5,300 in 2 sales, Jan 20 to Jan 20 · $360K likely match Form 4	Filing · EDGAR
Dec 17, 2025	27,563 · ~$2.3M	Dec 17, 2025	Sold as noticed Sold 27,763 in 5 sales, Dec 17 to Jan 20 · $2.3M Form 4 (1) · Form 4 (2)	Filing · EDGAR
Kymera Therapeutics KYMR · Morgan Stanley Smith Barney · 10b5-1 plan adopted Jun 18, 2024 · 3 notices
Jun 3, 2025	5,000 · ~$216K	Jun 3, 2025	Sold as noticed Sold 5,000 at $49.04 on Jun 3 · $245K Form 4	Filing · EDGAR
Dec 2, 2024	2,500 · ~$117K	Dec 2, 2024	Sold as noticed Sold 2,500 at $49.00 on Dec 2 · $123K Form 4	Filing · EDGAR
Sep 17, 2024	13,500 · ~$654K	Sep 17, 2024	Sold as noticed Sold 13,500 in 2 sales, Sep 17 to Sep 17 · $652K Form 4	Filing · EDGAR
Replimune Group · J.P. Morgan Securities · 10b5-1 plan adopted Feb 21, 2024 · 1 notice
May 23, 2024	79,710 · ~$473K	May 23, 2024	Not sold within 90 days	Filing · EDGAR
Replimune Group · J.P. Morgan Securities · 10b5-1 plan adopted Mar 15, 2023 · 1 notice
Jul 10, 2023	80,000 · ~$1.7M	Jul 10, 2023	Partly sold Sold 45,658 in 6 sales, Jul 10 to Sep 12 · $945K likely match Form 4 (1) · Form 4 (2) · Form 4 (3) · Form 4 (4)	Filing · EDGAR
Sales without a matching Form 144 · 15 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
—	—	—	Sold without notice Replimune Group: Sold 5,966 at $18.05 on May 16, 2023 · $108K	Filing · EDGAR
—	—	—	Notice not machine-readable Replimune Group: Sold 15,000 at $25.03 on Dec 9, 2022 · $375K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Replimune Group: Sold 3,507 at $14.59 on May 16, 2022 · $51K	Filing · EDGAR
—	—	—	Notice not machine-readable Replimune Group: Sold 25,800 at $35.09 on Aug 5, 2021 · $905K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Replimune Group: Sold 4,200 at $35.00 on Aug 4, 2021 · $147K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Replimune Group: Sold 12,538 at $33.17 on Jul 21, 2021 · $416K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Replimune Group: Sold 4,862 at $33.05 on Jul 20, 2021 · $161K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Replimune Group: Sold 4,600 at $33.37 on Jul 15, 2021 · $154K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Replimune Group: Sold 5,127 at $42.38 on Jan 19, 2021 · $217K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Replimune Group: Sold 600 at $43.24 on Jan 19, 2021 · $26K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Replimune Group: Sold 29,273 at $43.58 on Jan 15, 2021 · $1.3M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Replimune Group: Sold 20,000 at $45.02 on Jan 14, 2021 · $900K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Replimune Group: Sold 9,000 at $35.04 on Oct 14, 2020 · $315K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Replimune Group: Sold 7,000 at $30.15 on Oct 14, 2020 · $211K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Replimune Group: Sold 5,000 at $27.05 on Aug 31, 2020 · $135K (10b5-1 plan)	Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Kymera Therapeutics KYMR Director · filings 2020 to 2026 · sold $4.1M · $4.1M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 24, 2026	Grant or award from the company Stock Option (Right to Buy)	+6,068			6,068 direct	Filing · EDGAR
May 19, 2026	Option or RSU exercised or converted	+1,000	$31.20	$31K	1,000 direct	Filing · EDGAR
May 19, 2026	Option or RSU exercised or converted Stock Option (Right to Buy)	−1,000			9,000 direct	Filing · EDGAR
Mar 20, 2026	Option or RSU exercised or converted	+2,500	$49.10	$123K	2,500 direct	Filing · EDGAR
Mar 20, 2026	Sale under a 10b5-1 plan	−700	$77.71	$54K	1,800 direct	Filing · EDGAR
Mar 20, 2026	Sale under a 10b5-1 plan	−600	$79.24	$48K	1,200 direct	Filing · EDGAR
Mar 20, 2026	Sale under a 10b5-1 plan	−1,200	$79.94	$96K	0 direct	Filing · EDGAR
Mar 20, 2026	Option or RSU exercised or converted Stock Option (Right to Buy)	−2,500			0 direct	Filing · EDGAR
Feb 20, 2026	Option or RSU exercised or converted	+2,500	$49.10	$123K	2,500 direct	Filing · EDGAR
Feb 20, 2026	Sale under a 10b5-1 plan	−1,900	$87.06	$165K	600 direct	Filing · EDGAR
Feb 20, 2026	Sale under a 10b5-1 plan	−600	$88.10	$53K	0 direct	Filing · EDGAR
Feb 20, 2026	Option or RSU exercised or converted Stock Option (Right to Buy)	−2,500			2,500 direct	Filing · EDGAR
Jan 20, 2026	Option or RSU exercised or converted	+3,000	$31.20	$94K	3,000 direct	Filing · EDGAR
Jan 20, 2026	Option or RSU exercised or converted	+2,500	$49.10	$123K	5,500 direct	Filing · EDGAR
Jan 20, 2026	Sale under a 10b5-1 plan	−400	$66.68	$27K	5,100 direct	Filing · EDGAR
Jan 20, 2026	Sale under a 10b5-1 plan	−4,900	$67.99	$333K	200 direct	Filing · EDGAR
Jan 20, 2026	Sale under a 10b5-1 plan	−200	$68.52	$14K	0 direct	Filing · EDGAR
Jan 20, 2026	Option or RSU exercised or converted Stock Option (Right to Buy)	−3,000			10,000 direct	Filing · EDGAR
Jan 20, 2026	Option or RSU exercised or converted Stock Option (Right to Buy)	−2,500			5,000 direct	Filing · EDGAR
Dec 17, 2025	Option or RSU exercised or converted	+12,563	$49.10	$617K	12,563 direct	Filing · EDGAR
Dec 17, 2025	Option or RSU exercised or converted	+12,000	$27.67	$332K	24,563 direct	Filing · EDGAR
Dec 17, 2025	Option or RSU exercised or converted	+3,000	$31.20	$94K	27,563 direct	Filing · EDGAR
Dec 17, 2025	Sale under a 10b5-1 plan	−14,505	$81.56	$1.2M	13,058 direct	Filing · EDGAR
Dec 17, 2025	Sale under a 10b5-1 plan	−7,959	$82.34	$655K	5,099 direct	Filing · EDGAR
Dec 17, 2025	Sale under a 10b5-1 plan	−4,099	$83.45	$342K	1,000 direct	Filing · EDGAR
Dec 17, 2025	Sale under a 10b5-1 plan	−1,000	$84.07	$84K	0 direct	Filing · EDGAR
Dec 17, 2025	Option or RSU exercised or converted Stock Option (Right to Buy)	−12,563			7,500 direct	Filing · EDGAR
Dec 17, 2025	Option or RSU exercised or converted Stock Option (Right to Buy)	−12,000			0 direct	Filing · EDGAR
Dec 17, 2025	Option or RSU exercised or converted Stock Option (Right to Buy)	−3,000			13,000 direct	Filing · EDGAR
Jun 25, 2025	Grant or award from the company Stock Option (Right to Buy)	+16,000			16,000 direct	Filing · EDGAR
Jun 3, 2025	Option or RSU exercised or converted	+5,000	$29.55	$148K	5,000 direct	Filing · EDGAR
Jun 3, 2025	Sale under a 10b5-1 plan	−5,000	$49.04	$245K	0 direct	Filing · EDGAR
Jun 3, 2025	Option or RSU exercised or converted Stock Option (Right to Buy)	−5,000			24,127 direct	Filing · EDGAR
Dec 2, 2024	Option or RSU exercised or converted	+2,500	$29.55	$74K	2,500 direct	Filing · EDGAR
Dec 2, 2024	Sale under a 10b5-1 plan	−2,500	$49.00	$123K	0 direct	Filing · EDGAR
Dec 2, 2024	Option or RSU exercised or converted Stock Option (Right to Buy)	−2,500			29,127 direct	Filing · EDGAR
Sep 17, 2024	Option or RSU exercised or converted	+8,500	$29.55	$251K	8,500 direct	Filing · EDGAR
Sep 17, 2024	Option or RSU exercised or converted	+5,000	$14.18	$71K	13,500 direct	Filing · EDGAR
Sep 17, 2024	Sale under a 10b5-1 plan	−6,350	$47.75	$303K	7,150 direct	Filing · EDGAR
Sep 17, 2024	Sale under a 10b5-1 plan	−7,150	$48.75	$349K	0 direct	Filing · EDGAR
Sep 17, 2024	Option or RSU exercised or converted Stock Option (Right to Buy)	−8,500			31,627 direct	Filing · EDGAR
Sep 17, 2024	Option or RSU exercised or converted Stock Option (Right to Buy)	−5,000			7,000 direct	Filing · EDGAR
Jun 18, 2024	Grant or award from the company Stock Option (Right to Buy)	+16,000			16,000 direct	Filing · EDGAR
Jun 15, 2023	Grant or award from the company Stock Option (Right to Buy)	+12,000			12,000 direct	Filing · EDGAR
Jun 15, 2022	Grant or award from the company Stock Option (Right to Buy)	+12,000			12,000 direct	Filing · EDGAR
Jun 16, 2021	Grant or award from the company Stock Option (Right to Buy)	+20,063			20,063 direct	Filing · EDGAR
Sep 4, 2020	Grant or award from the company Stock Option (Right to Buy)	+40,127			40,127 direct	Filing · EDGAR

Replimune Group Chief Business Officer · filings 2018 to 2024 · sold $6.3M · $2.2M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Sep 12, 2023	Option or RSU exercised or converted	+300	$3.30	$990	263,736 direct	Filing · EDGAR
Sep 12, 2023	Sale under a 10b5-1 plan	−300	$20.00	$6K	263,436 direct	Filing · EDGAR
Sep 12, 2023	Option or RSU exercised or converted Employee Stock Option (right to buy)	−300			86,033 direct	Filing · EDGAR
Sep 11, 2023	Option or RSU exercised or converted	+5,358	$3.30	$18K	268,794 direct	Filing · EDGAR
Sep 11, 2023	Sale under a 10b5-1 plan	−5,358	$20.01	$107K	263,436 direct	Filing · EDGAR
Sep 11, 2023	Option or RSU exercised or converted Employee Stock Option (right to buy)	−5,358			86,333 direct	Filing · EDGAR
Aug 22, 2023	Option or RSU exercised or converted	+13,600	$3.30	$45K	277,036 direct	Filing · EDGAR
Aug 22, 2023	Option or RSU exercised or converted	+5,000	$15.50	$78K	282,036 direct	Filing · EDGAR
Aug 22, 2023	Sale under a 10b5-1 plan	−18,600	$20.01	$372K	263,436 direct	Filing · EDGAR
Aug 22, 2023	Option or RSU exercised or converted Employee Stock Option (right to buy)	−13,600			91,691 direct	Filing · EDGAR
Aug 22, 2023	Option or RSU exercised or converted Employee Stock Option (right to buy)	−5,000			35,750 direct	Filing · EDGAR
Aug 11, 2023	Option or RSU exercised or converted	+1,400	$3.30	$5K	264,836 direct	Filing · EDGAR
Aug 11, 2023	Sale under a 10b5-1 plan	−1,400	$20.00	$28K	263,436 direct	Filing · EDGAR
Aug 11, 2023	Option or RSU exercised or converted Employee Stock Option (right to buy)	−1,400			105,291 direct	Filing · EDGAR
Jul 10, 2023	Option or RSU exercised or converted	+15,000	$3.30	$50K	278,436 direct	Filing · EDGAR
Jul 10, 2023	Option or RSU exercised or converted	+5,000	$15.50	$78K	283,436 direct	Filing · EDGAR
Jul 10, 2023	Sale under a 10b5-1 plan	−17,923	$21.63	$388K	265,513 direct	Filing · EDGAR
Jul 10, 2023	Sale under a 10b5-1 plan	−2,077	$21.12	$44K	263,436 direct	Filing · EDGAR
Jul 10, 2023	Option or RSU exercised or converted Employee Stock Option (right to buy)	−15,000			106,691 direct	Filing · EDGAR
Jul 10, 2023	Option or RSU exercised or converted Employee Stock Option (right to buy)	−5,000			40,750 direct	Filing · EDGAR
May 16, 2023	Open-market or private sale	−5,966	$18.05	$108K	263,436 direct	Filing · EDGAR
Apr 1, 2023	Grant or award from the company	+40,000			269,402 direct	Filing · EDGAR
Apr 1, 2023	Grant or award from the company Employee Stock Option (right to buy)	+60,000			60,000 direct	Filing · EDGAR
Dec 9, 2022	Option or RSU exercised or converted	+15,000	$1.01	$15K	244,402 direct	Filing · EDGAR
Dec 9, 2022	Sale under a 10b5-1 plan	−15,000	$25.03	$375K	229,402 direct	Filing · EDGAR
Dec 9, 2022	Option or RSU exercised or converted Employee Stock Option (right to buy)	−15,000			36,203 direct	Filing · EDGAR
May 16, 2022	Open-market or private sale	−3,507	$14.59	$51K	229,402 direct	Filing · EDGAR
Apr 1, 2022	Grant or award from the company	+22,750			232,909 direct	Filing · EDGAR
Apr 1, 2022	Grant or award from the company Employee Stock Option (right to buy)	+34,125			34,125 direct	Filing · EDGAR
Aug 5, 2021	Option or RSU exercised or converted	+25,800	$15.50	$400K	235,959 direct	Filing · EDGAR
Aug 5, 2021	Sale under a 10b5-1 plan	−25,800	$35.09	$905K	210,159 direct	Filing · EDGAR
Aug 5, 2021	Option or RSU exercised or converted Employee Stock Option (right to buy)	−25,800			45,750 direct	Filing · EDGAR
Aug 4, 2021	Option or RSU exercised or converted	+4,200	$15.50	$65K	214,359 direct	Filing · EDGAR
Aug 4, 2021	Sale under a 10b5-1 plan	−4,200	$35.00	$147K	210,159 direct	Filing · EDGAR
Aug 4, 2021	Option or RSU exercised or converted Employee Stock Option (right to buy)	−4,200			71,550 direct	Filing · EDGAR
Jul 21, 2021	Option or RSU exercised or converted	+12,538	$1.01	$13K	222,697 direct	Filing · EDGAR
Jul 21, 2021	Sale under a 10b5-1 plan	−12,538	$33.17	$416K	210,159 direct	Filing · EDGAR
Jul 21, 2021	Option or RSU exercised or converted Employee Stock Option (right to buy)	−12,538			51,203 direct	Filing · EDGAR
Jul 20, 2021	Option or RSU exercised or converted	+4,862	$1.01	$5K	215,021 direct	Filing · EDGAR
Jul 20, 2021	Sale under a 10b5-1 plan	−4,862	$33.05	$161K	210,159 direct	Filing · EDGAR
Jul 20, 2021	Option or RSU exercised or converted Employee Stock Option (right to buy)	−4,862			63,741 direct	Filing · EDGAR
Jul 15, 2021	Option or RSU exercised or converted	+4,600	$1.01	$5K	214,759 direct	Filing · EDGAR
Jul 15, 2021	Sale under a 10b5-1 plan	−4,600	$33.37	$154K	210,159 direct	Filing · EDGAR
Jul 15, 2021	Option or RSU exercised or converted Employee Stock Option (right to buy)	−4,600			68,603 direct	Filing · EDGAR
Apr 1, 2021	Grant or award from the company	+34,165			210,159 direct	Filing · EDGAR
Apr 1, 2021	Grant or award from the company Employee Stock Option (right to buy)	+51,250			51,250 direct	Filing · EDGAR
Jan 19, 2021	Option or RSU exercised or converted	+5,727	$1.01	$6K	181,721 direct	Filing · EDGAR
Jan 19, 2021	Sale under a 10b5-1 plan	−600	$43.24	$26K	181,121 direct	Filing · EDGAR
Jan 19, 2021	Sale under a 10b5-1 plan	−5,127	$42.38	$217K	175,994 direct	Filing · EDGAR
Jan 19, 2021	Option or RSU exercised or converted Employee Stock Option (right to buy)	−5,727			73,203 direct	Filing · EDGAR
Jan 15, 2021	Option or RSU exercised or converted	+29,273	$1.01	$30K	205,267 direct	Filing · EDGAR
Jan 15, 2021	Sale under a 10b5-1 plan	−29,273	$43.58	$1.3M	175,994 direct	Filing · EDGAR
Jan 15, 2021	Option or RSU exercised or converted Employee Stock Option (right to buy)	−29,273			78,930 direct	Filing · EDGAR
Jan 14, 2021	Option or RSU exercised or converted	+20,000	$1.01	$20K	195,994 direct	Filing · EDGAR
Jan 14, 2021	Sale under a 10b5-1 plan	−20,000	$45.02	$900K	175,994 direct	Filing · EDGAR
Jan 14, 2021	Option or RSU exercised or converted Employee Stock Option (right to buy)	−20,000			108,203 direct	Filing · EDGAR
Dec 23, 2020	Option or RSU exercised or converted	+50,704	$1.75	$89K	175,994 direct	Filing · EDGAR
Dec 23, 2020	Option or RSU exercised or converted Employee Stock Option (right to buy)	−50,704			32,758 direct	Filing · EDGAR
Dec 11, 2020	Option or RSU exercised or converted	+12,590	$3.30	$42K	125,290 direct	Filing · EDGAR
Dec 11, 2020	Option or RSU exercised or converted Employee Stock Option (right to buy)	−12,590			121,691 direct	Filing · EDGAR

14 earlier transactions are in the filing list below.

All 50 Forms 3, 4, 5 and 144

Filed	Form	Company	Links
Jun 25, 2026	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
May 19, 2026	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
Mar 20, 2026	Form 144	Kymera Therapeutics KYMR	Filing · EDGAR
Mar 20, 2026	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
Feb 20, 2026	Form 144	Kymera Therapeutics KYMR	Filing · EDGAR
Feb 20, 2026	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
Jan 20, 2026	Form 144	Kymera Therapeutics KYMR	Filing · EDGAR
Jan 20, 2026	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
Dec 17, 2025	Form 144	Kymera Therapeutics KYMR	Filing · EDGAR
Dec 17, 2025	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
Jun 26, 2025	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
Jun 3, 2025	Form 144	Kymera Therapeutics KYMR	Filing · EDGAR
Jun 3, 2025	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
Dec 2, 2024	Form 144	Kymera Therapeutics KYMR	Filing · EDGAR
Dec 2, 2024	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
Sep 17, 2024	Form 144	Kymera Therapeutics KYMR	Filing · EDGAR
Sep 17, 2024	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
Jun 20, 2024	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
May 23, 2024	Form 144	Replimune Group	Filing · EDGAR
Sep 13, 2023	Form 4	Replimune Group	Filing · EDGAR
Aug 24, 2023	Form 4	Replimune Group	Filing · EDGAR
Aug 15, 2023	Form 4	Replimune Group	Filing · EDGAR
Jul 11, 2023	Form 4	Replimune Group	Filing · EDGAR
Jul 10, 2023	Form 144	Replimune Group	Filing · EDGAR
Jun 20, 2023	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
May 18, 2023	Form 4	Replimune Group	Filing · EDGAR
Apr 4, 2023	Form 4	Replimune Group	Filing · EDGAR
Dec 13, 2022	Form 4	Replimune Group	Filing · EDGAR
Jun 16, 2022	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
May 18, 2022	Form 4	Replimune Group	Filing · EDGAR
Apr 5, 2022	Form 4	Replimune Group	Filing · EDGAR
Aug 6, 2021	Form 4	Replimune Group	Filing · EDGAR
Jul 22, 2021	Form 4	Replimune Group	Filing · EDGAR
Jul 19, 2021	Form 4	Replimune Group	Filing · EDGAR
Jul 19, 2021	Form 4/A	Replimune Group	Filing · EDGAR
Jun 17, 2021	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
Apr 5, 2021	Form 4	Replimune Group	Filing · EDGAR
Jan 19, 2021	Form 4	Replimune Group	Filing · EDGAR
Dec 28, 2020	Form 4	Replimune Group	Filing · EDGAR
Dec 15, 2020	Form 4	Replimune Group	Filing · EDGAR
Oct 16, 2020	Form 4	Replimune Group	Filing · EDGAR
Sep 9, 2020	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
Sep 9, 2020	Form 3	Kymera Therapeutics KYMR	Filing · EDGAR
Sep 1, 2020	Form 4	Replimune Group	Filing · EDGAR
Apr 2, 2020	Form 4	Replimune Group	Filing · EDGAR
Dec 23, 2019	Form 4	Replimune Group	Filing · EDGAR
Apr 3, 2019	Form 4	Replimune Group	Filing · EDGAR
Dec 17, 2018	Form 4	Replimune Group	Filing · EDGAR
Jul 26, 2018	Form 4	Replimune Group	Filing · EDGAR
Jul 19, 2018	Form 3	Replimune Group	Filing · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.